SCHEMBL7133201

SCHEMBL7133201

OS1(O)CC(Sc2ccccc2)c2c(OCc3ccc(C(F)(F)F)cc3)cccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.39
PTPN1 P18031 3/20 0.38
RXRA P19793 3/20 0.38
RXRB P28702 3/20 0.38
RXRG P48443 3/20 0.38
PTPN2 P17706 2/20 0.38
PTPN6 P29350 2/20 0.38
PTPRC P08575 1/20 0.38
PTPRB P23467 1/20 0.38
PTPN11 Q06124 1/20 0.38
PPARD Q03181 3/20 0.37
SLC6A4 P31645 2/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
PPIA P62937 1/20 0.36
LIPE Q05469 1/20 0.36
KDM1A O60341 2/20 0.35
PPARG P37231 1/20 0.35
HTR1A P08908 1/20 0.34
SLC6A2 P23975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7133247 0.89 MAPT (0.42) SLC6A4LIPEKDM1AHTR1ASLC6A2
SCHEMBL7133205 0.88 MAOB (0.39) MAOBPTPN1RXRARXRBRXRG
SCHEMBL7131475 0.86 ABCB1 (0.40) SLC6A4LIPEKDM1AHTR1ASLC6A2
SCHEMBL7131030 0.83 MAPT (0.44) MAOBPPIAHTR1A
SCHEMBL7124900 0.80 HTR1A (0.44) SLC6A4HTR1A
SCHEMBL7128518 0.79 HTR1A (0.33) SLC6A4LIPEKDM1AHTR1ASLC6A2
SCHEMBL7126218 0.78 MEN1 (0.48) MAOBPPIAHTR1A
SCHEMBL7135326 0.78 CA1 (0.32) SLC6A4SLC6A2SLC6A3
SCHEMBL7131552 0.77 MEN1 (0.35)
SCHEMBL7695617 0.76 CYP11B1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6555555-B1 Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis ONO PHARMACEUTICAL CO., LTD. (JP) 2003-04-29 US disclosed
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US disclosed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO MAOB 4742/4885PTPN1 394/4885RXRA 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.